- About
- Projects
- Column 1
- Advancing Regulatory Science
- Animal Health & Veterinary Medicine
- Expanded Access
- FDA Patient Listening Sessions
- Column 2
- Food & Nutrition
- Improving Access to FDA Information
- Research
- Substance Use Disorders
- Column 1
- News and Events
- Expanded Access eRequest
Past Events
After nine months of suffering, isolation and economic downturn on an unprecedented international scale, the expedited development and approval of COVID-19 vaccines has shown us the light at the tunnel’s end.
In recent months, scientists and policymakers around the globe have rallied together with one common goal: to eliminate Covid-19.
Trust is health’s most valuable player
COVID-19 has made clear that the
December 17, 2020 (Washington, D.C.) As Americans patiently await their turn for COVID-19 vaccination, a group of leading medical, health equity and public policy experts discussed and answered questions a
US regulators have authorised the first coronavirus vaccine for emergency use, marking an inflection point in the
On a hot afternoon in August, Debbie Honeycutt walked into the crowded waiting room of the Medical Center for Clinical Research, an experimental-treatment facility tucked inside a squat office building in San Diego.
NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The Michael J.
Tom Skelton, CEO of Surescripts, recently spoke with Dr. Amy Abernethy of the FDA, about the impact of COVID-19 and the evolving data needs of public health.
Honorees to be recognized virtually on December 8, 2020
ZURICH/LONDON (Reuters) - With COVID-19 vaccine trial results looking positive, governments and pharmaceutical firms face their next daunting challenge: convincing the world to get inoculated.